Stockwinners Market Radar for December 11, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:06 EST Waterstone Financial announces 3.5M share repurchase program - Waterstone Financial announced that on December 10, its Board of Directors authorized a share repurchase program pursuant to which the company intends to repurchase up to 3.5M of its issued and outstanding shares, representing approximately 14.1% of its issued and outstanding shares of common stock. The repurchase program will commence on or about December 13. This share repurchase program follows the Board of Directors termination of the previous repurchase program during which the company repurchased a total of 1,453,554 shares of its common stock at a weighted average price of $17.16 per share.

17:01 EST Janssen EMEA announces conditional marketing authorization for Rybrevant - The Janssen Pharmaceutical Companies of Johnson & Johnson announced conditional marketing authorization of Rybrevant for the treatment of adult patients with advanced NSCLC with activating epidermal growth factor receptor exon 20 insertion mutations, after failure of platinum-based therapy. "Amivantamab is the first approved treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for NSCLC," the company stated. "This CMA follows other recent approvals for amivantamab, including the U.S. Food and Drug Administration, who approved the treatment in May 2021 for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Additional regulatory applications have been submitted and are being reviewed by other regulatory bodies worldwide," the company added.

16:37 EST Condor reports $7.94 per share liquidation distribution, intent to delist shares - Condor Hospitality Trust announced that its board of directors has approved a special dividend liquidation distribution of $7.94 per share of the company's common stock to its stockholders of record as of the close of business on December 27. The special dividend liquidation distribution will be paid on December 30. This special dividend liquidation distribution is being made in accordance with the company's voluntary plan of liquidation previously approved by its stockholders, whereby the company is engaged in its winding-up process. Upon completion of the winding-up process and dissolution, if any funds remain, such funds will be distributed to stockholders. The company also announced that it notified the NYSE of its intent to delist its common stock from the NYSE. The company expects to file a Form 25 with the Securities and Exchange Commission and NYSE American relating to the delisting of the common stock on or about December 20 and that its common stock will be suspended from trading on the NYSE American on or about December 31. The company does not expect that a trading market will develop for its Common stock following suspension of trading on NYSE. The company expects that the official delisting of its common stock will be effective on or about December 31.

16:31 EST Trinity Industries raises quarterly dividend to 23c from 21c per share - The quarterly cash dividend, representing Trinity's 231st consecutively paid dividend, is payable January 31, 2022 to stockholders of record on January 14, 2022.

16:11 EST AMCON Distributing announces $5.00 per share special dividend - AMCON Distributing Company announced that the board of AMCON declared a special cash dividend of $5.00 per common share. This cash dividend is payable on December 30 to shareholders of record as of December 23.

16:09 EST Trimble senior VP Kirkland sells 6,899 common shares - In a regulatory filing, Trimble senior VP James Kirkland disclosed the sale of 6,899 common shares of the company on December 8 at a price of $88.47 per share.

14:34 EST Tesla CEO says 'thinking of quitting' his jobs - Last night, Tesla CEO Elon Musk tweeted that he was "thinking of quitting" his jobs and "becoming an influencer full-time." Reference Link

14:02 EST Abbott says White to retire as Executive Chair, names CEO Ford as Chairman - Abbott announced that its board of directors has elected Chief Executive Officer Robert Ford as Chairman of the Board, effective today. Miles White, executive chairman and former CEO, will step down from the Abbott board effective today and will retire "after a remarkable 38-year career with the company," Abbott stated.

13:13 EST CDC says in 43 U.S. COVID-19 omicron cases studied, 79% were fully vaccinated - In its Morbidity and Mortality Weekly Report, the CDC stated in part: "During December 1-8, 2021, 22 U.S. states reported at least one COVID-19 case attributed to the Omicron variant. Among 43 cases with initial follow-up, one hospitalization and no deaths were reported... Details are available for 43 cases of COVID-19 attributed to the Omicron variant; 25, or 58%, were in persons aged 18-39 years. The earliest date of symptom onset was November 15 in a person with a history of international travel. Fourteen, or 33%, persons reported international travel during the 14 days preceding symptom onset or receipt of a positive test result. Among these cases of COVID-19 attributed to the Omicron variant, 34, or 79%, occurred in persons who completed the primary series of an FDA-authorized or approved COVID-19 vaccine greater than or equal to14 days before symptom onset or receipt of a positive SARS-CoV-2 test result, including 14 who had received an additional or booster dose; five of the 14 persons had received the additional dose less than14 days before symptom onset. Six, or 14%, persons had a documented previous SARS-CoV-2 infection. The most commonly reported symptoms were cough, fatigue, and congestion or runny nose." Reference Link

13:02 EST Baker Hughes reports U.S. rig count up 7 to 576 rigs

13:02 EST Sony Interactive Entertainment to acquire Valkyrie Entertainment - Sony Interactive Entertainment announced that it has entered into an agreement to acquire Seattle-based videogame developer, Valkyrie Entertainment. Valkyrie Entertainment will join PlayStation Studios as the 17th studio and will aid in the development of key PlayStation Studios franchises, the company said in a statement. "Valkyrie Entertainment is a highly adaptable and respected studio which has produced high-quality work on a range of platforms from console to PC; and a variety of styles from action to games-as-a-service titles," said Hermen Hulst, Head of PlayStation Studios. "Valkyrie's diverse capabilities will be welcomed by every team at PlayStation Studios as we continue to focus on delivering extraordinary gaming experiences." The day-to-day operations post-acquisition will continue to be run by Valkyrie Entertainment's current management team. Terms of this transaction including the acquisition cost are not disclosed due to contractual commitments.

12:52 EST PIK Stock trading resumes

12:43 EST Exxon Mobil VP Wojnar sells 12,512 common shares - In a regulatory filing, Exxon Mobil VP Theodore Wojnar, Jr. disclosed the sale of 12,512 common shares of the company on December 8 at a price of $62.5101 per share.

12:29 EST Meta offers new controls to help creators moderate comments - Facebook (FB), also known as Meta (MVRS), said it is rolling out a few updates for creators, including new controls to help creators more easily moderate comments, live chat support tests to troubleshoot account issues, and a webinar series on how to stay safe on Facebook. "We're adding more controls to help you manage the conversation around your content like blocking a user and new accounts they create, and improving how you hide unwanted comments on your posts," the company said. "With the hide action now available next to each comment, you can quickly hide comments with one click and easily view all hidden comments in a single place by changing the comment filter view on your posts. For keyword blocking, you can now automatically hide comments with variations of words that use numbers, symbols, or different spellings. We're also testing Moderation Assist, which - similar to Admin Assist for Groups - makes it easy to set criteria to automatically moderate comments on your posts, reducing how much time is spent on comment moderation. You can select from a list of rules to automatically hide certain types of comments on your posts such as comments with links, images, and more." Reference Link

12:11 EST Puma Biotechnology presents updates from Phase II SUMMIT trial - Puma Biotechnology presented an update from its Phase II SUMMIT trial at the ongoing 2021 San Antonio Breast Cancer Symposium Annual Meeting. The data presented was from the cohort of patients with hormone receptor-positive, HER2-mutant metastatic breast cancer, exposed to CDK4/6 inhibitors, and treated with a combination of neratinib with fulvestrant and trastuzumab and a separate cohort of patients with metastatic triple negative breast cancer with a HER2 mutation treated with the combination of neratinib plus trastuzumab. The presentation, entitled "Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial," is being presented at an oral session by Komal Jhaveri, MD, FACP, Medical Oncologist at Memorial Sloan Kettering Cancer Center, on December 10 at 11:00 a.m. CST. The Phase II SUMMIT trial is an open-label, multicenter, multinational study to evaluate the safety and efficacy of neratinib administered daily to patients who have solid tumors with activating HER2 mutations or lung cancers with EGFR exon 18 mutations. In the HER2-mutant, hormone receptor-positive, metastatic breast cancer cohort, patients who have previously received CDK4/6 inhibitors were previously enrolled in a non-randomized cohort and received 240 mg of neratinib per day, 500 mg fulvestrant on day 1 and 15 of Cycle 1 and then 8mg/kg trastuzumab every 4 weeks initially and then 6mg/kg trastuzumab every 3 weeks thereafter. In the HER2-mutant, triple negative metastatic breast cancer cohort, patients received 240 mg of neratinib per day and 8mg/kg body weight trastuzumab initially and then 6mg/kg trastuzumab every 3 weeks. All patients received anti-diarrheal prophylaxis with loperamide alone for the first two treatment cycles. The SUMMIT trial was later amended to randomize hormone receptor-positive, HER2-mutant metastatic breast cancer patients to receive either: the combination of neratinib, trastuzumab and fulvestrant, the combination of fulvestrant and trastuzumab, or fulvestrant alone. Once randomized, patients received either neratinib plus fulvestrant plus trastuzumab, fulvestrant plus trastuzumab, or fulvestrant in 1:1:1 ratio. All patients received anti-diarrheal prophylaxis with loperamide alone for the first two treatment cycles. In the non-randomized cohort, for the 26 patients with HR+, HER2-mutated MBC who had previously received CDK4/6 inhibitors, the efficacy results showed that for the patients who received neratinib plus fulvestrant plus trastuzumab, 12 patients experienced a confirmed objective response, all of which were partial responses, and 15 patients experienced clinical benefit. The median duration of response was 14.4 months and the median progression-free survival was 8.2 months. For the randomized portion of the trial, for the patients with HR+, HER2-mutated MBC who had previously received CDK4/6 inhibitors, no patient in either the fulvestrant plus trastuzumab or fulvestrant alone arm experienced a confirmed objective response. In the 7 randomized patients who received the combination of neratinib, trastuzumab and fulvestrant, 2 patients experienced a confirmed objective response, including one complete response and one partial response, and 2 patients experienced clinical benefit. The median duration of response was not reached and the median progression-free survival was 6.2 months. For all 33 patients with HR+, HER2-mutated MBC, who had previously received CDK4/6 inhibitors, who received the combination of neratinib plus trastuzumab plus fulvestrant, the efficacy results showed that 14 patients experienced a confirmed objective response, including one complete response and 13 partial responses, and 17 patients experienced clinical benefit. The median duration of response was 14.4 months and the median progression-free survival was 7.0 months. Based on the results from the randomized portion of the trial, for patients with hormone receptor-positive, HER2-mutant metastatic breast cancer, the Independent Data Monitoring Committee recommended closing enrollment to the fulvestrant plus trastuzumab and fulvestrant alone arms of the trial and recommended continuing enrollment in the neratinib plus trastuzumab plus fulvestrant arm of the trial. To date, the Company has enrolled 19 additional patients in this triplet arm of the trial. For the 18 patients with HER2-mutant triple negative breast cancer who received fulvestrant plus trastuzumab, 6 patients experienced a confirmed objective response, including one complete response and 5 partial responses, and 7 patients experienced clinical benefit. The median duration of response has not been reached and the median progression-free survival was 6.2 months. The safety profile observed in patients treated with neratinib in the SUMMIT study was consistent with that observed previously in metastatic patients with HER2 amplified tumors. The interim safety results of the study showed that the most frequently observed adverse event was diarrhea. For the 33 safety-evaluable HR-positive breast cancer patients who received the combination of neratinib plus trastuzumab plus fulvestrant, 15 patients reported grade 3 diarrhea. One patient permanently discontinued neratinib due to diarrhea. For the 18 safety-evaluable triple negative breast cancer patients who received the combination of neratinib plus trastuzumab, 3 patients reported grade 3 diarrhea. No patient permanently discontinued neratinib due to diarrhea.

12:05 EST Phillips 66 announces 2022 capital program of $1.9B - Phillips 66 (PSX) announced its 2022 capital program of $1.9B, which includes $992M for sustaining capital and $916M for growth capital. Approximately 45% of growth capital supports lower-carbon opportunities, the company noted. The Midstream capital plan of $703M, which includes Phillips 66 Partners (PSXP), comprises $426M for growth projects and $277M for sustaining projects. Growth capital will be directed toward completing construction of Sweeny Frac 4 and repayment of its 25% share of the Bakken Pipeline joint venture's debt due in 2022. Midstream growth capital also includes Emerging Energy opportunities to advance the company's lower-carbon efforts. In Refining, Phillips 66 plans to invest $896M, with $488M for reliability, safety and environmental projects. Refining growth capital of $408M is primarily for the reconfiguration of the San Francisco Refinery in Rodeo, California, as part of the Rodeo Renewed project. Upon expected completion in early 2024, the facility will initially have over 50,000 barrels per day, or 800 million gallons per year, of renewable fuel production capacity, "making it one of the world's largest facilities of its kind," the company said. Refining growth capital will also support opportunities for high-return, low-capital projects. "The 2022 capital program demonstrates our commitment to disciplined capital allocation. Our plan for sustaining capital reflects our ongoing focus on operating excellence to ensure the safety and reliability of our operations. We are also investing in returns-focused growth opportunities, including projects that will help us advance a lower-carbon future. In addition to a disciplined capital program, we will continue to prioritize debt reduction and returns to shareholders," said Greg Garland, Chairman and CEO of Phillips 66.

12:00 EST Blue Apron falls -10.9% - Blue Apron is down -10.9%, or -$1.16 to $9.52.

12:00 EST Figs falls -16.6% - Figs is down -16.6%, or -$5.18 to $26.04.

12:00 EST Sprinklr rises 15.4% - Sprinklr is up 15.4%, or $2.08 to $15.60.

11:18 EST Yucaipa expects to close SIGNA Sports United combination on December 14 - Yucaipa Acquisition Corporation announced that, subject to shareholder approval, it expects all conditions to be met or waived to complete its previously announced business combination with SIGNA Sports United. The transaction is expected to raise at least $484M from YAC trust proceeds and a fully committed, upsized private placement of common stock from institutional and high-tech investors, sovereign wealth funds and high net-worth individuals. The company said, "As previously disclosed, the Company believes its short-term revenue growth targets for the current fiscal year will be adversely affected by the on-going COVID-19 related supply chain disruptions and will likely land in the range of EUR 1.4B to EUR 1.55B on a full-year pro forma basis. However, the Company reiterates that it is very confident demand remains strong, the strategic consolidation opportunities are huge and the mid and long-term mega-trends behind the business are accelerating. The Company expects to continue on its strong growth track once the COVID-19 related supply chain situation normalizes."

10:39 EST Kansas City Southern stockholders approve merger with Canadian Pacific - Kansas City Southern (KSU) announced that the company's stockholders have voted to approve the previously announced combination with Canadian Pacific Railway (CP) at today's virtual special meeting of stockholders. Of the 64.5M shares voting at the special meeting, approximately 99.6% were cast in favor of the adoption of the proposed merger agreement, the company noted. On December 8, CP's stockholders voted to approve the issuance of the CP common shares to KCS stockholders in connection with the proposed merger. The transaction is expected to close on Tuesday, December 14. KCS stockholders will receive $90 in cash and 2.884 CP shares for each KCS common share held and $37.50 in cash for each KCS preferred share held. Immediately upon close, ownership of KCS will be held in a voting trust pending the Surface Transportation Board's review and approval of CP's proposed control of KCS, which is expected to occur in the fourth quarter of 2022.

10:19 EST Allied Healthcare trading resumes

10:00 EST Figs falls -10.6% - Figs is down -10.6%, or -$3.31 to $27.91.

10:00 EST Boxed falls -12.7% - Boxed is down -12.7%, or -$1.52 to $10.41.

10:00 EST Sprinklr rises 13.3% - Sprinklr is up 13.3%, or $1.80 to $15.31.

09:47 EST Chewy falls -6.2% - Chewy is down -6.2%, or -$3.48 to $52.82.

09:47 EST Boxed falls -9.8% - Boxed is down -9.8%, or -$1.17 to $10.76.

09:47 EST Sprinklr rises 11.5% - Sprinklr is up 11.5%, or $1.55 to $15.06.

09:37 EST Everbridge trading resumes

09:35 EST Celcuity presents results of Phase 1b study of gedatolisib with palbociclib - Celcuity presented a poster at the 2021 San Antonio Breast Cancer Symposium with updated results from a four-arm Phase 1b expansion study. This study evaluated gedatolisib, a first-in-class pan-PI3K/mTOR inhibitor, in combination with palbociclib, a CDK4/6 inhibitor and endocrine therapy in women with ER+/HER2- advanced breast cancer. The poster presented data as of a May 10, 2021 data cutoff. Preliminary data from this Phase 1b study was presented earlier this year with results as of a January 11, 2021 data cut-off. Consistent with the previously released results, the addition of gedatolisib to palbociclib and endocrine therapy demonstrated promising antitumor activity in both first and later line settings for ER+/HER2- ABC that compared favorably to historical controls. A significant objective response rate was also observed in patients refractory to their last treatment or who had received two or more lines of prior treatment for advanced breast cancer. Gedatolisib was well tolerated with manageable toxicity and a low number of patients discontinued treatment due to an adverse event. Phase 1B Study Design and Results: Patients with ER+/HER2- advanced breast cancer were treated in one of four arms. Palbociclib, letrozole, and fulvestrant were administered at standard doses. Gedatolisib 180 mg was intravenously administered weekly in Arms A, B, and C and three weeks on/one week off in Arm D. The primary endpoint was ORR and secondary endpoints were safety, duration of response, and progression free survival. Patient assessment was conducted by the investigator. A summary of key results follows below: Arm A: Patients who were treatment naive in the ABC setting: ORR: 85%; PFS: 31.1 months. Arm B: Patients who received prior endocrine therapy without a CDK4/6 inhibitor: ORR: 77%; PFS: 11.9 months. Arm C: Patients who received prior treatment with a CDK4/6 inhibitor; greater than2 prior therapies for ABC: 66% of patients; ORR: 32%; PFS: 5.1 months. Arm D - Patients who received prior treatment with a CDK4/6 inhibitor; greater than 2 prior therapies for ABC: 33% of patients; ORR: 63%; PFS: 12.9 months. Results from an exploratory comparative and a longitudinal intrapatient analysis were also presented for two sub-groups of Arm C and Arm D patients: patients who had the same number of prior lines of treatment; and patients who had similar durations of treatment with their immediate prior therapy. The two analyses were performed to isolate the effect of the different gedatolisib schedules used in Arm C and Arm D on patient response. Key findings from the analyses are presented below: The ORR in Arm D relative to Arm C was superior irrespective of the number of prior therapies for ABC. Patients who had received one prior line of therapy were 1.7 times more likely to report an objective response in Arm D than Arm C. Patients who had received 2 or more prior lines of therapy were 2.4 times more likely to report an objective response in Arm D than Arm C. The median duration of treatment with gedatolisib was significantly longer in Arm D relative to Arm C, irrespective of the treatment period of their immediate prior therapy. For patients who had progressed on their prior treatment in less than six months, the median duration of treatment for Arm D patients was 3.33 times longer than patients in Arm C. The ORR for this sub-group of Arm D and C patients was 71% and 0% respectively. For patients who had progressed on their prior treatment in less than 12 months, Arm D patients remained on treatment 2.10 times longer than patients in Arm C. The ORR for this sub-group of Arm D and C patients was 73% and 15% respectively. Because duration of treatment tends to decline in subsequent lines of therapy, a longitudinal intrapatient analysis was performed to compare the efficacy of the gedatolisib regimen to the immediate prior regimen for the sub-group of Arm C and D patients who remained on their prior therapy less than six and 12 months. The analysis was performed using duration of treatment because progression free survival data was not available for patients' immediate prior therapy. For Arm D patients who progressed on their prior therapy in less than six months, the median duration of gedatolisib treatment was 2.6 times longer than their immediate prior treatment period. For Arm C patients, the ratio between the time on gedatolisib versus immediate prior therapy was 0.8. For Arm D patients who had progressed on prior therapy in less than 12 months, the median duration of gedatolisib treatment was 1.8 times longer than their immediate prior treatment period. For Arm C patients, the ratio between time on gedatolisib versus immediate prior therapy duration was 0.9. Overall, this exploratory analysis of ORR and duration of treatment found significantly higher ORR and longer duration of treatment in Arm D vs. Arm C patients who progressed within six months and within 12 months on their prior therapy. In addition, ORR was superior in Arm D relative to Arm C in patients irrespective of the number of prior therapies for ABC. This suggests that Arm D's gedatolisib/palbociclib synchronized dosing schedule may have played a significant role in the different outcomes between the Arms. The study of gedatolisib in combination with palbociclib and endocrine therapy also demonstrated that the treatment was well tolerated with side effects managed by available standards of care. No Grade 5 event occurred; the most common Grade 3-4 adverse events were stomatitis and neutropenia. Less than 10% of all patients, and only one patient in Arm D, discontinued treatment due to an adverse event. Fewer patients experienced Grade 3-4 adverse events associated with PI3K/mTOR inhibition compared to data reported for other products in this class. Across all study arms, Grade 3-4 hyperglycemia was observed in less than or equal to7% of patients, AST and ALT elevation in less than or equal to10% of patients, diarrhea and colitis in less than or equal to7% of patients, pneumonitis in less than or equal to4% of patients. These results reflect gedatolisib's differentiated pharmacokinetic properties and indicate that gedatolisib can be safely combined with other targeted agents.

09:31 EST Pfizer receives EC approval for 100 mg, 200 mg doses of Cibinqo - Pfizer announced that the European Commission, or EC, has approved the 100 mg and 200 mg doses of Cibinqo, an oral, once-daily, Janus kinase 1, or JAK1, inhibitor, for the treatment of moderate-to-severe atopic dermatitis, or AD, in adults who are candidates for systemic therapy. Additionally, a 50 mg dose was approved to treat moderate-to-severe AD specifically in patients with moderate and severe renal impairment or certain patients receiving treatment with inhibitors of cytochrome P450 2C19. The approval of Cibinqo was based on the results of five clinical studies of more than 2,800 patients including four Phase 3 studies and an ongoing long-term open label extension study. Cibinqo demonstrated meaningful improvements across measures of symptom relief and disease control versus placebo. In one trial including an active control arm with dupilumab, which evaluated patients on background topical medicated therapy, Cibinqo 200 mg was associated with a greater improvement in itch relief after two weeks than dupilumab. Cibinqo also demonstrated a consistent safety profile across trials, including in a long-term extension study, showing a favorable benefit-risk profile. The most common adverse events reported with Cibinqo in 5% of patients were nausea and headache. The most frequent serious adverse reactions were infections.

09:28 EST CVS Health raises quarterly dividend 10% to 55c per share - The dividend is payable on February 1, 2022, to holders of record on January 21, 2022.

09:17 EST IMAC's The Back Space announces Nashville location reaches 100 active members - IMAC Holdings (IMAC) announced that its first location of The Back Space has reached 100 active members. The Back Space, located within Walmart (WMT) stores, are retail healthcare centers specializing in chiropractic adjustments, nerve and muscle stimulation, and percussion tool therapies for soft tissue recovery, muscle relaxation, and spinal wellness. Services are offered on a walk-in and appointment basis, priced at $25 per treatment, with memberships available for $65 per month that are valid at any The Back Space location.

09:11 EST Crypto stocks track higher as bitcoin trades up from overnight lows - The price of bitcoin is up about 5% from yesterday evening's lows, testing the upside of $50,000 level. Stocks levered to bitcoin prices are also tracking higher in the pre-market session, with Bit Digital (BTBT) up 3.3%, Riot Blockchain (RIOT) up 3.8%, Marathon Digital (MARA) up 5.4%, and Coinbase Global (COIN) up 3.1%.

09:04 EST The Brick opens first new Calgary store in 12 years - The Brick is celebrating the grand opening of its new store in Calgary, the retailer's first in the city since 2009. Strategically placed in the busy south end off Macleod Trail, the Shawnessy location officially opens to the public today and is ideally located to serve customers in Calgary as well as outlying communities such as High River, Okotoks, Black Diamond and Turner Valley.

09:04 EST Red Rock Resorts reports preliminary results of modified Dutch auction - Red Rock Resorts announced preliminary results of its "modified Dutch auction" tender offer which expired at 12:00 midnight, New York City time, at the end of the day on December 9. Based on the preliminary count by American Stock Transfer & Trust Company, a total of 6,921,149 shares of RRR's Class A Common Stock, par value $0.01 per share, were properly tendered and not properly withdrawn at or below a purchase price of $51.50 per Share, including 1,992,710 Shares that were tendered by notice of guaranteed delivery. In accordance with the terms and conditions of the tender offer and based on the preliminary count by the Depositary, RRR expects to purchase all 6,921,149 shares through the tender offer at a price of $51.50 per Share, for an aggregate cost of approximately $356.4M, excluding fees and expenses relating to the tender offer. Included in the 6,921,149 Shares that RRR expects to purchase are 125,033 Shares that RRR has elected to purchase pursuant to its right to purchase up to an additional 2% of its outstanding Shares. The total of 6,921,149 Shares that RRR expects to purchase represents approximately 10.13% of the total number of Shares outstanding, or 6.12% of the total number of Shares outstanding assuming exchange of all shares of the company's Class B Common Stock and limited liability interests in Station Holdco LLC, as of December 9.

09:02 EST Information Analysis Incorporated announces $10M equity financing - Information Analysis announced it has obtained subscriptions for the sale of 3,289,525 Units at a price of $3.04 per Unit in a private investment in public equity financing. Each Unit consists of a share of $0.01 par value common stock of the Company and the right to receive a warrant exercisable for .20 shares of common stock which equates to one share for every five Units purchased. Each such warrant is exercisable commencing January 1, 2023 through December 31, 2026 at a price of $4.50 for each whole share. The price per Unit was determined using the 5-day Volume Weighted Average Price from November 26, 2021 to and including December 2, 2021. The Company estimates net proceeds from the PIPE will be approximately $9.9 million, after deducting attorneys fees and other expenses. No commissions were paid in connection with this financing. The financing was led by the Company's Chairman and CEO, Mr. Jamie Benoit, and newly-appointed board member Chip DiPaula, with participation from existing investors, Company executives, and members of the IAI Board of Directors. Several limited partners of Marlinspike Capital also made leading investments in the PIPE.

09:01 EST Fat Brands continues Middle East expansion with 10-store Libya deal - FAT Brands, parent company of Fatburger, Johnny Rockets, and 13 other restaurant concepts, announces a new deal to enter Libya with 10 new franchised restaurants. The new stores will be made up of five co-branded Johnny Rockets and Hurricane Grill & Wings locations and five co-branded Fatburger and Buffalo's Express restaurants, which are slated to open over the next three years. Franchisee Al Majmoua Al Moutakamila is spearheading the 10-store deal which will also mark the first co-branded Johnny Rockets and Hurricane Grill & Wings location to date in the region. On the heels of recently announced expansion plans in United Arab Emirates, Kingdom of Saudi Arabia, Bahrain, Qatar, and Kuwait, the Libya development deal further reinforces FAT Brands' commitment to growing in the Middle East. "The Middle East is an important growth area for FAT Brands," said FAT Brands CEO Andy Wiederhorn. "With a growing appreciation for quick-service restaurants in the region, we look forward to bringing our beloved burger and wing brands to Libya. Similarly, we are excited to unveil the first co-branded Johnny Rockets and Hurricane Grill & Wings location in the region. We saw tremendous success when we co-branded Fatburger and Buffalo's Express and expect to see the same with this burger and wing pairing with locals."

09:01 EST Synopsys announces $1B share repurchase program - Synopsys announced that its Board of Directors has approved a new stock repurchase program with authorization to purchase up to $1B of common stock. The program replaces Synopsys' prior stock repurchase program, which was originally approved by Synopsys' Board of Directors in 2002.

08:50 EST Dassault Aviation notes Finland chooses U.S. with F-35 - The company said, "Dassault Aviation takes note of the sovereign decision of the Finnish authorities to choose the American solution for the replacement of the F-18 Air Component. Once again, we notice and regret an American preference prevailing in Europe. For their part, Dassault Aviation and its industrial partners are continuing to develop the Rafale's operational capabilities, in the service of France and of countries that want to have a first-rate air force with full sovereignty, as Greece and Croatia have recently chosen in Europe, and others outside Europe."

08:39 EST Sonoco Products provides update on sustainability strategy focus - Elizabeth Rhue, Staff Vice President of Sustainability, outlined Sonoco's global sustainability strategy, which is targeting significant reduction of the Company's carbon footprint while providing customers with more sustainable products. "We are focused on three areas," Rhue explained. "Products - As in what products we will be delivering to the marketplace, including thinking through material selection and how we leverage emerging technologies; Infrastructure - How does current and future infrastructure play into end-of-life treatment of our products; and Partnerships - How we leverage relationships across a number of different areas, from academia to customer to our supply chain to deliver on our goals." Earlier this year, Sonoco established Scope 1, 2 and 3 emission reduction goals validated by the Science-Based Targets initiative. By 2030, the Company has pledged to reduce Scope 1 and 2 greenhouse gas emissions by 25 percent, and in cooperation with suppliers and customers, the Company is committed to reducing Scope 3 emission by 13.5 percent. "Because we know it will not be easy to meet these commitments, we have put together a cross-functional team focused on ensuring we are incorporating sustainability and environmental metrics into our business strategy and incentives. This includes establishing business-level greenhouse gas emission targets, implementing shadow carbon pricing as part of our capital approval process and improving reporting and transparency of environmental data."

08:35 EST Sonoco Products targets annual EBITDA growing to $1B by 2026 - Sonoco provided an overview of its five-year strategic plan and 2022 financial guidance during a virtual meeting with investors. Featured presenters at the meeting included: Howard Coker, President and Chief Executive Officer; Rodger Fuller, Executive Vice President; Julie Albrecht, Vice President and Chief Financial Officer; and Elizabeth Rhue, Staff Vice President of Sustainability. The presentation from today's event is available on the Investor Relations section of Sonoco's website at www.sonoco.com. President and CEO Howard Coker discussed the Company's value-creation strategy that is focused on Sonoco being viewed as a benchmark yield and stability packaging company and targeting to grow organic annual earnings before interest, taxes, depreciation and amortization to $1 billion by 2026. Key elements of the strategy include: Further capital investment in the Company's core Consumer and Industrial businesses to augment growth and generate strong returns; Executing an operating strategy to implement a series of "self-help" actions that are expected to generate approximately $180 million in incremental annual EBITDA over the next five years; Simplifying Sonoco's structure to create a more effective and efficient organization and managing the Company's portfolio for "fit" around fewer, bigger businesses; Continuing to consider and pursue acquisitions that improve the portfolio and complement the strategy beyond the path to $1 billion in annual EBITDA.

08:33 EST iBio announces partial adjournment of annual meeting to December 22 - iBio announced that its annual meeting of stockholders scheduled for and convened yesterday has been partially adjourned to December 22, 2021 at 9:00 a.m. Eastern Time. A quorum was present at yesterday's Annual Meeting, and Proposals 1, 2 and 3 put forth in the definitive proxy statement received the requisite votes for approval. The Company's stockholders also approved Proposal 6 for the purpose of continuing to solicit votes in favor of Proposal 4 and Proposal 5. With over 60% of all shares voted, iBio stockholders are in favor of the reverse split and authorized share decrease by approximately a 2-to-1 margin. Results of votes cast "FOR" Proposals 4 and 5 to-date are 64% and 67%, respectively. Additionally, both of the leading proxy advisory firms have recommended that stockholders vote "FOR" the proposals. With a clear plurality of the vote in favor of the proposals and strong, independent third-party support for the reverse split and authorized share decrease, the Company is allowing additional time for stockholders holding approximately 40% of the shares that have yet to be voted the opportunity to express their views. Proposals 4 and 5 require a majority of all shares outstanding to vote "FOR" the measures, not just a plurality of the vote.

08:32 EST Assure Holdings announces results of annual general meeting - Assure Holdings announced that it held its virtual annual general meeting of shareholders yesterday and that all matters submitted to the shareholders of the Company for approval as set out in the Company's definitive proxy statement dated November 9, 2021, were approved by the requisite majority of votes cast at the Meeting, including: Electing all nominees to the board of directors of the Company, including Martin Burian, John Farlinger, Preston Parsons, Christopher Rumana, Steven Summer and John Flood. Re-appointing Baker Tilly US as auditors of the Company for the ensuing year. Approving the executive compensation for the Company's named executive officers. Approving the frequency of advisory votes on executive compensation, being every three years. Approving certain amendments to the Company's stock option plan. Approving certain amendments to the Company's equity incentive plan. Approving the Company's new stock incentive plan. Approving the Company's new employee stock purchase plan. Pursuant to the terms of the 2021 Stock Incentive Plan and 2021 Employee Stock Purchase Plan, the maximum aggregate number of shares that may be issued under all awards under such plans, plus any shares granted under the 2020 Option Plan and 2020 Equity Incentive Plan, is 2,367,260 shares. The amendments to the 2020 Option Plan, the amendments to the 2020 Equity Incentive Plan, the 2021 Stock Incentive Plan and the 2021 Employee Stock Purchase Plan each remain subject to the approval of the TSX Venture Exchange (the "TSXV").

08:31 EST T. Rowe Price reports preliminary AUM $1.63T at November 30 - Client transfers from mutual funds to other portfolios, including trusts and separate accounts, were $1.1B in November, and $4.2B for the quarter-to-date period ended November 30.

08:24 EST Finland selects Lockheed Martin's F-35 Lightning II as its next fighter - The Finnish Government has announced Lockheed Martin's 5th Generation F-35 Lightning II is the aircraft selected from its HX Fighter Program. By selecting the F-35, Finland gains a significant capability to ensure stability in the region. The Finnish Air Force will receive 64 F-35A multirole stealth fighters, a robust weapons package, a sustainment solution tailored to Finland's unique security of supply requirements, as well as a comprehensive training program.

08:17 EST Xplore Dundee orders 12 NFI electric double-deck buses - NFI Group subsidiary Alexander Dennis Limited announced that the ADL and BYD electric vehicle partnership has supplied 12 British-built electric double deck buses to bus operator Xplore Dundee. These new vehicles will reduce greenhouse gas emissions and deliver cleaner, quieter, more sustainable mobility along one of Scotland's most polluted streets.

08:10 EST Schweitzer-Mauduit closes sale of Spotswood, New Jersey property for $35M - SWM International has finalized the sale of its former Spotswood, New Jersey facility to an undisclosed buyer, with net proceeds of approximately $35M. Net proceeds from the transaction will be used to reduce Company debt. As previously disclosed, the Company closed its Spotswood, NJ facility at the end of 2020 as the Company transitioned to a newly developed manufacturing technology to better support the site's customer.

08:09 EST BeyondSpring announces analysis of data from Phase 3 PROTECTIVE-2 trial - BeyondSpring Pharmaceuticals announced the presentation of additional analyses from the Phase 3 portion of the PROTECTIVE-2 trial evaluating the combination of plinabulin and pegfilgrastim for the prevention of chemotherapy-induced neutropenia, CIN, in breast cancer patients at the 2021 San Antonio Breast Cancer Symposium, SABCS, held both live and virtually from December 7-10, 2021. Poster Title: Mechanistic evidence associated with the benefit of plinabulin significantly reducing bone pain in breast cancer patients treated with TAC and pegfilgrastim. Key Findings: Patients treated with pegfilgrastim and plinabulin experienced less bone pain than did patients treated with pegfilgrastim only; Treatment with plinabulin may mitigate the need for compensatory hematopoiesis and intracavitary pressure build-up, resulting in bone pain sensations; Patients treated with pegfilgrastim and plinabulin had a higher absolute neutrophil count at the nadir; The depth of ANC nadir was statistically significantly correlated with bone pain scores. Poster Title: Combination plinabulin+pegfilgrastim had better toxicity management and health related quality-of-life compared to Peg alone in early-stage breast cancer patients treated with taxotere, doxorubicin and cyclophosphamide. Key Findings: Adding plinabulin to pegfilgrastim decreases toxicity and improves HrQoL among patients with breast cancer receiving TAC; The adverse event profile among patients treated with plinabulin and pegfilgrastim was shifted towards lower grade AEs; Adding plinabulin to pegfilgrastim prevented a decline in HrQoL scores for mobility, self-care, daily activities, pain and anxiety.

08:08 EST Amdocs files fiscal 2021 Annual Report - Amdocs has filed its Annual Report on Form 20-F for the fiscal year ended September 30, 2021 with the U.S. Securities and Exchange Commission. The annual report is available through the Company's website. Upon the request of a shareholder of the Company, the Company will promptly provide to such shareholder a copy of the 2021 annual report, free of charge.

08:06 EST Atlantic Union Bankshares announces $100M share repurchase authorization - The Board of Directors of Atlantic Union Bankshares Corporation has authorized the repurchase of up to $100M worth of the Company's common stock through December 9, 2022. Shares of common stock may be purchased under the Repurchase Program periodically in open market transactions or privately negotiated transactions at prevailing market prices, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended.

08:03 EST Infinity Pharmaceuticals presents updated data from MARIO-3 study - Infinity Pharmaceuticals presented updated data from the ongoing MARIO-3 clinical study during the 2021 San Antonio Breast Cancer Symposium, or SABCS. MARIO-3 is the company's ongoing Phase 2 study evaluating eganelisib in combination with atezolizumab and nab-paclitaxel in frontline metastatic triple negative breast cancer, or TNBC. This data update includes 50 patients enrolled and 44 evaluable as of the October 2 data cutoff date, with a median duration of follow up of 9.9 months. Of evaluable patients, tumor reduction was observed in 92.8% of patients with PD-L1 positive tumors and 85.2% of patients with PD-L1 negative tumors. Overall, 92.8% DCR in patients with PD-L1 positive tumors and 81.4% DCR in patients with PD-L1 negative tumors. In patients with PD-L1+ tumors, median PFS in MARIO-3 was 11 months, a 47% improvement in mPFS compared to the 7.5 months reported for atezolizumab and nab-paclitaxel alone in IMpassion130. In patients with PD-L1- tumors, median PFS in MARIO-3 was 7.3 months, a 30% improvement compared to the 5.6 months reported for atezolizumab and nab-paclitaxel alone in IMpassion130 . In total, 72% of the 32 PD-L1 (+) and PD-L1(-) patients treated since the June 26 data cut remain on treatment and 67% of the PD-L1(-) patients who reached the median PFS of 7.3 months remain on treatment. MARIO-3 did not demonstrate any new safety signals compared to benchmark trials, and its safety profile was consistent with expectations for the three component drugs. The most common Grade 3 or higher treatment-related TEAEs were hepatic AEs; neutropenia AEs; skin AEs; fatigue, diarrhea and peripheral sensory neuropathy and vomiting and weight decreased. Seven patients discontinued treatment for treatment-related TEAEs and nine patients had treatment-related SAEs. Quantification across 11 paired tumor biopsies shows increased immune activation and decreased immune suppression including an increase in CD8+ T cells, activated T cells, and anti-tumor M1 macrophages and a decrease in tumor cells and pro-tumor M2 macrophages resulting in an increase in the M1:M2 ratio. Paired tumor biopsy data show 5 of 8 patients with PD-L1(-) tumors converting to PD-L1(+) two months after treatment utilizing the same 1% PD-L1 cutoff standard used in the benchmark IMpassion130 study. PD-L1 expression also increased in the three patients with PD-L1(+) tumors who started the study above the 1% cutoff. None of the patients converting to PD-L1(+) or patients with PD-L1(+) tumors who experienced increased PD-L1 expression had disease progression.

08:01 EST Manning & Napier reports preliminary AUM $22B as of November 30 - Compared with $22.5B at October 31, and $22B at September 30.

07:40 EST Centene sees FY22 health benefits ratio of 87.6%-88.2% - Sees FY22: Selling, general and administrative expense ratio of 7.9%-8.4%, which excludes depreciation expense as it will be separately disclosed from SG&A expense in 2022. Adjusted SG&A expense ratio of 7.8%-8.3%, which excludes $132M-$147M of acquisition related expenses. Effective tax rate of 25.5%-26.5%. Adjusted effective tax rate of 25.0%-26.0%.

07:34 EST AnPac Bio announces publication on CDA cancer detection technology - AnPac Bio-Medical Science announced its joint technical paper on novel Cancer Differentiation Analysis Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online on November 30, 2021 by the Expert Review of Molecular Diagnostics, a peer-reviewed international medical journal that has an impact factor of 5.2. The title of the published paper is "Development and Evaluation of Cancer Differentiation Analysis Technology: A Novel Biophysics-Based Screening Method". The co-authors of the paper included several leading medical institutions in China, including the School of Medicine, Shanghai Jiao Tong University, and Department of Statistics and Data Management at Children's Hospital of Fudan University. The paper reported the mechanism of CDA technology, as well as an extensive, multi-year, multi-cancer screening validation work that included a two-stage study design. This cross-sectional study of CDA testing in the initial stage, included a routine health checkup involving 75,942 individuals which was followed by a prospective population-based cohort study involving 1,957 individuals. The studies concluded that the CDA test is useful for cancer screening with high specificity and moderate sensitivity among healthy individuals and continues to lay both the conceptual and practical foundation for AnPac Bio's novel biophysics-based test for cancer screening. Based on results from the study, the published technical paper also cited a number of advantages of CDA technology which include its potential suitability for health screening, estimated cost quite comparable or lower than that of other screening methods, and its multi-cancer screening ability for large population.

07:32 EST Iron Mountain to acquire ITRenew for $725M in cash - Iron Mountain has entered into a definitive agreement to acquire ITRenew, a data center lifecycle management solutions company. Upon closing, Iron Mountain will acquire 80% of the outstanding shares of ITRenew on a cash- and debt-free basis for approximately $725M in cash, with the remaining 20% acquired within three years of close for a minimum enterprise value of $925M. Previous investor ZMC, a private equity firm, will exit its position as part of this transaction. Following the close of the transaction, ITRenew will form the platform for Iron Mountain's Global IT Asset Lifecycle Management business. Under the terms of the agreement, Iron Mountain will acquire at closing 80% of the shares of ITRenew for approximately $725M in cash. The remaining 20% will be acquired in cash within three years from close, with a minimum payment of $200M and the final amount subject to the performance of the business. The transaction implies a minimum enterprise value of $925M, which corresponds to a purchase multiple of approximately 12x based on trailing twelve month EBITDA as of September 30. The transaction is expected to close in Q1 of 2022, subject to regulatory approval and other customary closing conditions.

07:31 EST BridgeBio reports inducement grants under Nasdaq listing rule - BridgeBio Pharma announced that on December 6, 2021, the compensation committee of BridgeBio's board of directors granted nine new employees restricted stock units for an aggregate of 12,073 shares of the Company's common stock. All of the above-described awards were made under BridgeBio's 2019 Inducement Equity Plan. The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019.

07:29 EST North Mountain Merger Corporation (Class A Stock) trading halted, news pending

07:07 EST CareTrust REIT appoints David Sedgwick to succeed CEO Greg Stapley - The Board of Directors of CareTrust REIT announced the appointment of David Sedgwick as CEO, to be effective as of January 1, 2022. Sedgwick will succeed founding Chairman and CEO Greg Stapley, who will continue to serve as CareTrust's Executive Chairman during an approximately six-month transition period, following which he and his wife Deborah will commence a three-year, full-time volunteer assignment for The Church of Jesus Christ of Latter-day Saints. The Board also announced that Diana Laing has been appointed as Lead Independent Director. Sedgwick, who has been with CareTrust since 2014, currently serves as CareTrust's President and COO and will retain his title as the Company's President.

07:06 EST Xortx announces publication of study of hospitalized COVID-19 patients - XORTX Therapeutics announces the online publication of the peer reviewed paper entitled "Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19" in the American Journal of Nephrology. This paper highlights the results of the study that was conducted by the Icahn School of Medicine at Mount Sinai in partnership with XORTX and focused on the clinical outcomes of 834 patients with COVID-19 infection who were hospitalized at Mount Sinai Hospital in New York City. As is typical for COVID-19 infection, the patients were very sick with approximately 60% developing acute kidney injury, AKI, and with 31.7% dying in hospital. The study investigated the potential predictive role of serum uric acid on clinical outcomes. Serum uric acid was elevated in nearly 38 percent of subjects when first measured. Dr. Allen Davidoff, CEO of XORTX added, "The results of this study support the Company's provisional patent filings in March 2020 and 2021 that contain claims to the use of any uric acid lowering agents to prevent and treat acute kidney, acute organ injury or sepsis associated with COVID-19 infection. Resulting from this study is a more fulsome understanding that measurement of uric acid at the time of hospitalization, rapid uric acid lowering in patients who show evidence of acute kidney injury plus hyperuricemia may improve outcomes in hospitalized patients." This study authored by the Mount Sinai team contains several key findings that will help in understanding the acute injury occurring in hospitalized patients with accompanying COVID-19 infection, including: 1/ A large proportion of individuals hospitalized with COVID-19 arrive at hospital, or soon after admission, develop acute kidney injury and concerningly high serum uric acid concentrations. 2/ High serum uric acid is associated with increased biomarker indicators of kidney and heart injury and increased propensity toward sepsis. 3/ Hyperuricemia has historically been associated with increased systemic and local inflammation and in the setting of COVID-19 may play a potential role for inflammation in kidney, heart and other organs. 4/ Patients with hyperuricemia and COVID-19 have worse outcomes.

07:05 EST Corcentric to go public via combination with North Mountain Merger - Corcentric and North Mountain Merger Corp. announced that they have entered into a definitive agreement to consummate a business combination that would result in Corcentric becoming a publicly listed company. Upon the closing of the Transaction, the combined entity will be named Corcentric. The company is expected to have an implied pro forma enterprise value of approximately $1.2B at closing. Following the closing of the Transaction, the Corcentric executive management team will continue to be led by Founder and Chief Executive Officer Douglas Clark and President and Chief Operating Officer Matthew Clark. Thomas Sabol will serve as Chief Financial Officer and Mark Joyce will serve as the Company's Executive Vice President and Chief Accounting Officer. The Transaction implies a pro forma enterprise value of the combined company of approximately $1.2B, representing an 8.1x multiple to 2022 expected adjusted revenue of $149M. The Transaction is expected to deliver approximately $182M in gross proceeds, comprising NMMC's approximately $132M of cash held in trust and $50M of fully committed PIPE financing from anchor investors, including Wellington Management and Millais Limited, an affiliate of the Sponsor. Under the terms of the Transaction, Corcentric's existing shareholders will convert their ownership stakes into equity of the combined company and are expected to own approximately 81% of the post-combination company immediately following the closing of the transaction. Bregal Sagemount, a prominent growth equity firm, will continue as a shareholder of Corcentric. In addition, existing Corcentric equity holders have the potential to receive an earnout of additional shares of common stock of the Company, if certain stock price targets are met as set forth in the definitive merger agreement. The Transaction has been unanimously approved by the Boards of Directors of both Corcentric and North Mountain. The Transaction, which is expected to close in the second quarter of 2022, will require the approval of the stockholders of both Corcentric and North Mountain and is subject to other customary closing conditions, including the receipt of requisite regulatory approvals.

07:04 EST Barrick Gold publishes Human Rights report - Barrick Gold Corporation published its report on Human Rights outlining the company's revised policies and standards and their implementation since the merger with Randgold Resources. The publication of the report coincides with the United Nations' Human Rights Day, which commemorates the day, in 1948, when the UN General Assembly adopted the Universal Declaration of Human Rights. The theme for this year is Equality. During 2020, Barrick updated several standards including the Use of Force Standard and developed a new Voluntary Principles on Security and Human Rights Standard. It also revised, updated and restarted its human rights program, in which every operation conducts a human rights assessment on a two- to three-year cycle. To date, all high- and medium-risk sites have been assessed, with Kibali in the Democratic Republic of Congo and Loulo-Gounkoto in Mali completed during 2021. Barrick trained its employees and contractors in these updated standards and policies and worked with independent human rights experts, Avanzar, to develop online modules to ensure that human rights training was not hampered by Covid-19 related travel and social distancing restrictions. Barrick also developed 'train the trainer' programs to empower its site security leadership with the knowledge and skills to deliver long-term training to their teams and local public security forces. These programs were successfully implemented at the North Mara and Bulyanhulu operations in Tanzania during 2021. In the report, president and chief executive Mark Bristow said that recognizing and respecting human rights was a core value for Barrick, and its Human Rights Policy was one of the first the group updated following the merger with Randgold Resources. It is codified in Barrick's standalone Human Rights Policy and informed by the expectations of the UN Guiding Principles on Business and Human Rights, the Voluntary Principles on Security and Human Rights and the OECD Guidelines for Multinational Enterprises. The report also provides an insight into Barrick's salient human rights issues such as non-discrimination in the workplace, health and safety, working conditions, resettlement, security, water and the rights of indigenous people; and reflects on Barrick's legacy human rights challenges as well as the actions the company has taken to remedy these.

07:01 EST Oncolytics presents 'positive' safety data from Phase 2 IRENE trial - Oncolytics Biotech announced a positive interim safety update from the investigator-sponsored, phase 2 IRENE trial in a poster presentation at the 2021 San Antonio Breast Cancer Symposium. The IRENE trial is designed to evaluate the safety and efficacy of pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab for second- or third-line treatment of patients with metastatic triple-negative breast cancer. Safety data from the trial show that the combination has been well-tolerated, as no safety concerns have been noted in any of the five patients enrolled in the trial at the time of reporting. The trial remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute of New Jersey and the Ohio State University Comprehensive Cancer Center.

06:46 EST Lazard reports preliminary AUM approximately $267.4B as of November 30 - The month's AUM included market depreciation of $5.8B, foreign exchange depreciation of $3.4B and net outflows of $3.1B.

06:33 EST Figs CFO Jeffrey Lawrence to retire, Daniella Turenshine to succeed - FIGS announced that Jeffrey Lawrence, its CFO, has decided to retire, effective December 24. Jeff joined FIGS in December 2020, coming out of retirement to help lead FIGS' highly successful initial public offering earlier this year. FIGS is excited to announce that Daniella Turenshine, its Senior Vice President of Finance and Strategy, has been appointed FIGS' CFO, effective December 24. Daniella joined FIGS in 2018 and led FIGS' finance team for over two years before Jeff joined the company, and she has continued to serve on FIGS' senior executive team and as a leader on the finance team. Prior to FIGS, she served as Vice President at Garnett Station Partners, a growth-oriented investment firm where she helped to build out a high-growth consumer products company.

06:08 EST Lumber Liquidators to complete name change to LL Flooring Holdings on Jan. 1 - Lumber Liquidators Holdings announced that it expects to complete its corporate entity name change to LL Flooring Holdings effective January 1, 2022, upon satisfying all applicable legal and regulatory requirements. The company's stock will continue to be listed on the NYSE under the ticker symbol "LL" and the CUSIP identifier for the stock will not change. No action is needed from current stockholders.

06:03 EST ChipMOS reports November revenue $80.8M, up 9% - ChipMOS reported its unaudited consolidated revenue for the month of November. Revenue for the month of November was $80.8M, an increase of 9% compared to November 2020 and a decrease of 2.3% compared to October. Revenue increased 21% in the first eleven months of 2021 compared to the first eleven months of 2020. The company noted the slight decline sequentially in November revenue compared to October reflects one less working day in November.

05:18 EST Genentech announces new follow-up data for CITYSCAPE trial - Genentech, a member of Roche, announced new follow-up efficacy, safety and patient-reported outcomes, or PROs, data from the Phase II CITYSCAPE trial, investigating the novel anti-TIGIT cancer immunotherapy tiragolumab plus Tecentriq compared with Tecentriq alone as an initial treatment for people with PD-L1-positive metastatic non-small cell lung cancer, or NSCLC. The full results are being featured as an oral presentation in the Proffered Paper session 2 at the European Society for Medical Oncology, or ESMO, Immuno-Oncology Congress. After 2.5 years median follow-up, tiragolumab plus Tecentriq continued to show an improvement in the intention-to-treat, or ITT, population, driven by the PD-L1-high population. In the ITT population, the combination reduced the risk of disease worsening or death by 38% and improved overall response rates, or ORR, compared with Tecentriq alone. A predefined exploratory analysis in the PD-L1-high population showed a 71% reduction in the risk of disease worsening or death and a clinically meaningful improvement in ORR with the combination compared with Tecentriq alone. The analysis also showed that tiragolumab plus Tecentriq improved overall survival, or OS, a secondary endpoint of the study, in the ITT population, which was driven by the PD-L1-high population. After 2.5 years median follow-up, median OS was 23.2 vs. 14.5 months in the ITT population. The exploratory data in the PD-L1-high population showed a clinically meaningful OS improvement. The median was not reached for the tiragolumab regimen and is projected to be greater than 30.3 months based on the lower confidence interval vs.12.8 months. Data suggest that the combination was generally well-tolerated, showing similar rates of Grade 3-4 treatment-related adverse events, or AEs, when adding tiragolumab to Tecentriq compared with Tecentriq alone. The most common all cause AEs seen with the combination were infusion-related reactions, stiffness, dry skin, fatigue and rash. After longer follow-up, no new safety signals were observed with the combination. Patients generally reported minimal-to-moderate symptoms and generally maintained their quality of life compared with the start of treatment. PRO data from this exploratory analysis showed that lung symptoms, such as dyspnea and pain, did not appear to deteriorate with the addition of tiragolumab to Tecentriq.

05:05 EST Kraft Heinz to acquire 85% stake in Just Spices, terms undisclosed - Kraft Heinz announced that it has reached an agreement to acquire an 85% stake in Germany-based Just Spices. The remaining 15% ownership stake will be retained by Just Spices' three founders, who will continue on with the company and focus on driving the business and its international growth. Launched in 2014, Just Spices is an start-up with annual sales of approximately EUR 60M. The deal is subject to customary closing conditions, including merger control approval, and is expected to be completed in the first quarter of 2022.